RSV Disease in the Elderly
Pathogenesis of RSV Disease in the Elderly
1 other identifier
observational
1,401
1 country
1
Brief Summary
Respiratory syncytial virus (RSV) causes sickness and deaths in older people every winter. This study will investigate how aging affects the body's immune response (body's response to disease) to RSV. About 2000 people, age 21 and older, who reside in the upstate NY area, will be recruited. Two groups of subjects will be studied. The 1st group of volunteers will be recruited prior to the start of RSV season in year 1 of the study. These volunteers will include healthy people and people with various medical conditions. The 2nd group of volunteers will be patients admitted to Rochester General Hospital for acute respiratory illness. Procedures will include drawing blood from a vein in the arm (2 tablespoons), collecting nasal swabs, and collecting sputum. Volunteers may participate in study related procedures for up to 3 years.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2005
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 3, 2005
CompletedFirst Submitted
Initial submission to the registry
October 27, 2005
CompletedFirst Posted
Study publicly available on registry
October 31, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 28, 2008
CompletedStudy Completion
Last participant's last visit for all outcomes
May 28, 2008
CompletedFebruary 4, 2019
April 1, 2011
2.7 years
October 27, 2005
January 31, 2019
Conditions
Keywords
Eligibility Criteria
You may qualify if:
- Prospective Cohort
- Greater than or equal to 21 years of age
- Able to provide written consent
- Telephone contact available
- Will reside in the Upstate New York area throughout the winter months
- Hospital Cohort
- Greater than or equal to 21 years of age
- Able to provide written consent or legal guardian able to provide written consent
- Telephone contact available
- Symptoms of respiratory tract infection for less than or equal to 30 days duration. Symptoms can be all or any of the following: nasal congestion, cough, new or increased sputum or dyspnea, sore throat, with or without fever
You may not qualify if:
- Prospective Cohort
- Known immunosuppressive condition including: HIV, active cancer currently receiving chemotherapy, hematological malignancy, autoimmune disorders.
- Documented RSV infection in the previous year
- Participation in previous RSV vaccine study
- Hospital Cohort
- Known immunosuppressive condition including: HIV, active cancer currently receiving chemotherapy, hematological malignancy, autoimmune disorders.
- Symptoms of a respiratory infection for longer than 30 days.
- Participation in prior RSV vaccine study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Rochester General Hospital
Rochester, New York, 14621, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- NIH
Study Record Dates
First Submitted
October 27, 2005
First Posted
October 31, 2005
Study Start
October 3, 2005
Primary Completion
May 28, 2008
Study Completion
May 28, 2008
Last Updated
February 4, 2019
Record last verified: 2011-04